ATE395087T1 - Hgf zur gentherapie der karidomyopathie - Google Patents

Hgf zur gentherapie der karidomyopathie

Info

Publication number
ATE395087T1
ATE395087T1 AT00964686T AT00964686T ATE395087T1 AT E395087 T1 ATE395087 T1 AT E395087T1 AT 00964686 T AT00964686 T AT 00964686T AT 00964686 T AT00964686 T AT 00964686T AT E395087 T1 ATE395087 T1 AT E395087T1
Authority
AT
Austria
Prior art keywords
hgf
caridomyopathy
gene therapy
cardiac muscle
cardiac
Prior art date
Application number
AT00964686T
Other languages
English (en)
Inventor
Ryuichi Morishita
Yoshiaki Taniyama
Toshio Ogihara
Original Assignee
Anges Mg Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anges Mg Inc filed Critical Anges Mg Inc
Application granted granted Critical
Publication of ATE395087T1 publication Critical patent/ATE395087T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT00964686T 1999-10-08 2000-10-05 Hgf zur gentherapie der karidomyopathie ATE395087T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP28853299 1999-10-08

Publications (1)

Publication Number Publication Date
ATE395087T1 true ATE395087T1 (de) 2008-05-15

Family

ID=17731468

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00964686T ATE395087T1 (de) 1999-10-08 2000-10-05 Hgf zur gentherapie der karidomyopathie

Country Status (10)

Country Link
US (1) US6989374B1 (de)
EP (1) EP1136083B1 (de)
JP (1) JP3865632B2 (de)
KR (1) KR20010093804A (de)
CN (2) CN101085363A (de)
AT (1) ATE395087T1 (de)
AU (1) AU775965B2 (de)
CA (1) CA2354029C (de)
DE (1) DE60038869D1 (de)
WO (1) WO2001026694A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2230819C (en) * 1995-08-29 2009-04-14 Sumitomo Pharmaceuticals Co., Ltd. Medicament comprising hgf gene
CN1182874C (zh) * 1999-10-29 2005-01-05 安增子摩祺株式会社 糖尿病性局部缺血疾病的基因治疗制剂
JP2005097118A (ja) * 2000-07-18 2005-04-14 Yoshiki Sawa Ｈｇｆ遺伝子からなる細胞移植定着促進剤
US20020061587A1 (en) 2000-07-31 2002-05-23 Piero Anversa Methods and compositions for the repair and/or regeneration of damaged myocardium
US7862810B2 (en) 2000-07-31 2011-01-04 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium
US7547674B2 (en) * 2001-06-06 2009-06-16 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium
CA2446946A1 (en) 2001-05-09 2002-11-14 Anges Mg, Inc. Gene transfer of angiogenic factor for skin disease
WO2003024462A1 (en) 2001-09-19 2003-03-27 Henry Ford Health System Cardiac transplantation of stem cells for the treatment of heart failure
AU2002349583B2 (en) 2001-11-28 2007-11-22 Anges Mg, Inc. Genetic remedies for neurodegenerative diseases
US20080213348A1 (en) * 2002-06-06 2008-09-04 Anges Mg, Inc. Agents for gene therapy of cerebrovascular disorders
DE60332748D1 (de) 2002-10-02 2010-07-08 Anges Mg Inc Arzneimittel gegen hörfunktionsstörungen
AU2003221120A1 (en) * 2003-04-01 2004-11-01 Masashi Komeda Remedy for cardiomyopathy
US20090012498A1 (en) * 2004-10-29 2009-01-08 Yoshiki Sawa Gene therapy for treatment of heart failure
US7696170B2 (en) 2005-01-24 2010-04-13 Kringle Pharma Inc. Fibrosis inhibitor for implanted organ
CN101200721B (zh) * 2006-09-18 2011-06-08 复旦大学附属中山医院 人心肌保护基因及其用途
WO2009062143A2 (en) 2007-11-09 2009-05-14 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium using cytokines and variants thereof
AU2008334036B2 (en) 2007-11-30 2014-05-29 New York Medical College Methods of reducing transplant rejection and cardiac allograft vasculopathy by implanting autologous stem cells
US8512696B2 (en) 2007-11-30 2013-08-20 Autologous, Llc Methods of isolating non-senescent cardiac stem cells and uses thereof
EP2227238A2 (de) 2007-11-30 2010-09-15 New York Medical College Zusammensetzungen mit vaskulären und myozyten-vorläuferzellen und anwendungsverfahren davon
JP4831551B2 (ja) * 2008-11-06 2011-12-07 国立大学法人名古屋大学 非虚血性心筋障害に対する医薬

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0452457B1 (de) 1989-11-03 1997-08-20 Vanderbilt University Verfahren zur in vivo-verabreichung von funktionsfähigen fremden genen
JP2777678B2 (ja) 1990-06-11 1998-07-23 敏一 中村 組換ヒト肝実質細胞増殖因子及びその製造方法
DE69133492T2 (de) 1990-06-11 2006-08-10 Nakamura, Toshikazu Rekombinanter menschlicher Hepatozytwachstumsfaktor und Verfahren zu seiner Herstellung
US5652225A (en) 1994-10-04 1997-07-29 St. Elizabeth's Medical Center Of Boston, Inc. Methods and products for nucleic acid delivery
US5792453A (en) * 1995-02-28 1998-08-11 The Regents Of The University Of California Gene transfer-mediated angiogenesis therapy
WO1996030073A1 (en) * 1995-03-30 1996-10-03 Heartport, Inc. Endovascular cardiac venting catheter and method
US5756122A (en) 1995-06-07 1998-05-26 Georgetown University Liposomally encapsulated nucleic acids having high entrapment efficiencies, method of manufacturer and use thereof for transfection of targeted cells
CA2230819C (en) * 1995-08-29 2009-04-14 Sumitomo Pharmaceuticals Co., Ltd. Medicament comprising hgf gene
US6121246A (en) 1995-10-20 2000-09-19 St. Elizabeth's Medical Center Of Boston, Inc. Method for treating ischemic tissue
WO1999036103A1 (en) 1998-01-16 1999-07-22 Mcgill University Prevention and treatment of neuropathy by hepatocyte growth factor
EP1132098B1 (de) 1999-09-21 2010-05-26 AnGes MG, Inc. Gentherapie für zerebrale gefässerkrankungen
CN1182874C (zh) 1999-10-29 2005-01-05 安增子摩祺株式会社 糖尿病性局部缺血疾病的基因治疗制剂
EP1532987A4 (de) 2002-06-06 2005-12-28 Anges Mg Inc Mittel für die gentherapie bei zerebrovaskulären erkrankungen

Also Published As

Publication number Publication date
KR20010093804A (ko) 2001-10-29
CN101085363A (zh) 2007-12-12
EP1136083A1 (de) 2001-09-26
WO2001026694A1 (fr) 2001-04-19
JP3865632B2 (ja) 2007-01-10
EP1136083B1 (de) 2008-05-14
CN1293922C (zh) 2007-01-10
CN1337884A (zh) 2002-02-27
AU7556900A (en) 2001-04-23
AU775965B2 (en) 2004-08-19
CA2354029C (en) 2012-01-10
US6989374B1 (en) 2006-01-24
CA2354029A1 (en) 2001-04-19
EP1136083A4 (de) 2005-11-16
DE60038869D1 (de) 2008-06-26

Similar Documents

Publication Publication Date Title
DE60038869D1 (de) Hgf zur gentherapie der karidomyopathie
DE60026996D1 (de) Plasmabehandlungsapparat, dessen elektrodenstruktur und struktur der bühne
WO2000054813A3 (en) Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
FI961755A0 (fi) Yhdistelmäadenovirusvektori ja menetelmiä sen käyttämiseksi
PL339735A1 (en) Pappiloma virus capsomer vaccine compositions and methods of applying them
DE69517957D1 (de) 5-substituierte derivate von mycophenolsäure
ATE407949T1 (de) Charakterisierung der proteinfamilie von soc/crac kalziumkanälen
EP1202736A4 (de) Verwendung von nikotin in der angiogenese und der vaskulogenese
DE60121988D1 (de) Kombinationstherapie mit antidiabetischen und antikonvulsiven mitteln
WO2002100390A3 (en) Improved method of treating the syndrome of coronary heart disease risk factors in humans
ATE320435T1 (de) Oxazolo-, thiazolo- und selenazolo-(4,5- c)naphthyridin-4-amine und analoge davon
GR3036686T3 (en) Therapeutic uses of bactericidal/permeability increasing protein products
NO20005884D0 (no) Kombinasjonsterapi for behandling av bipolare forstyrrelser
ATE232396T1 (de) Oxydiertes thymosin beta 4
WO2003045332A3 (en) Methods and compositions for treating lesions of the respiratory epithelium
CY1112957T1 (el) Μη νευροτοξικοι παραγοντες, οι οποιοι ενεργοποιουν το πλασμινογονο για τη θεραπευτικη αγωγη εγκεφαλικου επεισοδιου
CY1108667T1 (el) Ανασυνδυασμενοι φορεις ιου περιεχοντες το ανθρωπινο γονιδιο του ενεργοποιητη πλασμινογονου ουροκινασης και η χρηση τους στην αγωγη της ινωσεως του ηπατος.
CY1106133T1 (el) Αγωνιστες υποδοχεα 2 παραγοντα απελευθερωσης κορτικοτροπινης
DE60037978D1 (de) Interferon ähnliche moleküle, und deren verwendungen
ATE296894T1 (de) Genverabreichende vektoren mit gewebetropismus für glatte muskelzellen und/oder endothelzellen
EA200200319A1 (ru) Белок iren, его получение и использование
DE60019104D1 (de) Gentherapy von lungenkrankheiten
WO2000017375A3 (en) Method to treat haemophilia by in vivo gene therapy with retroviral vectors
DE69531678D1 (de) Rekombinatie viren,ihre herstellung und ihre verwendung in der gentherapie
FI19992648L (fi) Lääkkeen luovutuslaitteita ja menetelmiä virus- ja mikrobi-infektioiden ja riutumissyndrooman hoitoon

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties